Related Experiment Video
Updated: Jun 23, 2025
10:45
Light-mediated Formation and Patterning of Hydrogels for Cell Culture Applications
Published on: September 29, 2016
13.0K
Targeting Hydrogel for Intelligent Recognition and Spatiotemporal Control in Cell-Based Therapeutics
Weilin Hou1, Wei Mao1,2, Jun Sun1,3
1School of Environmental and Chemical Engineering, Jiangsu University of Science and Technology, Zhenjiang, Jiangsu, 212003, P. R. China.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|June 14, 2024
Summary
A novel composite hydrogel (PCF-FAMxP) integrates imaging and therapy for smarter cancer treatment. This platform enhances tumor immunogenic cell death (ICD) and immune checkpoint blockade (ICB) therapy, guided by MRI and fluorescence imaging.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Cancer Therapy
Background:
- Traditional cancer theranostics face challenges in efficiency and predictability.
- Developing integrated platforms for simultaneous imaging and therapy is crucial for improved outcomes.
Purpose of the Study:
- To develop a smart drug delivery system combining imaging and therapy for enhanced cancer treatment.
- To create a composite hydrogel (PCF-FAMxP) for spatiotemporally controlled drug release and multimodal imaging.
Main Methods:
- Fabrication of a thermosensitive hydrogel (polyvinyl alcohol-carboxylic acid hydrogel, PCF) and a multifunctional nanoparticle (Fe3O4@Au/Mn(Zn)-4-carboxyphenyl porphyrin/polydopamine, FAMxP).
- Integration of PCF and FAMxP to form a composite hydrogel for targeted drug delivery and in situ release.
- Utilizing magnetic resonance imaging (MRI) and fluorescence imaging (FI) for tumor visualization and treatment guidance.
- Implementing immunogenic cell death (ICD) and immune checkpoint blockade (ICB) therapy, including photothermal, photodynamic, and chemodynamic approaches.
Main Results:
- The PCF-FAMxP composite hydrogel demonstrated targeted cell recognition via folate receptors.
- Near-infrared light triggered thermal dissolution of the hydrogel, enabling slow, in situ release of FAMxP.
- FAMxP release within tumor cells was pH-dependent, facilitating chemodynamic, photothermal, and photodynamic therapy-induced ICD.
- Combined therapy significantly enhanced tumor treatment effectiveness when integrated with anti-programmed cell death ligand 1 (ICB).
Conclusions:
- The developed PCF-FAMxP composite hydrogel offers a promising approach for advanced cancer theranostics.
- This platform enables cooperative MRI/FI-guided targeted therapeutic pathways, improving treatment efficacy.
- The simple composition and integrated functionalities represent an updated drug design strategy for complex tumor treatments.
